Early Life and Education

Gareth Sheridan ​is originally from Terenure, ​a suburb of south Dublin, Ireland. he pursued studies in business and management at the Dublin Institute​ of Technology, graduating in 2012. Prior to‌ his presidential campaign, ‌Sheridan founded ⁣Nutriband in April 2011.

Nutriband: Transdermal Patch Technology

Nutriband aimed to ​deliver medication through the skin using transdermal patches. The company’s flagship product, AVERSA, was marketed as an abuse-deterrent transdermal patch incorporating ⁢aversive agents to discourage misuse and⁢ accidental exposure to drugs. By 2016,Sheridan had relocated to Florida to focus on developing Nutriband.

Nasdaq Listing and Regulatory Scrutiny

After several attempts, Sheridan successfully listed nutriband on the Nasdaq ‌stock exchange in December 2021. However, the ⁣company’s operations soon ⁣came under⁤ scrutiny from US regulatory agencies.

During the initial⁢ stages of his 2024⁤ presidential campaign, revelations ‍surfaced regarding a cease and desist‌ agreement reached between Sheridan and his company, Nutriband, and the US government in 2018.This agreement included⁣ a $25,000 fine levied against Sheridan personally.

FDA Violations and SEC Investigation

The 2018 document ​revealed that Nutriband had begun marketing its transdermal patches – designed for delivering both vitamins and drugs – in the ‍United States without obtaining prior authorization‌ from the Food and Drug Administration (FDA). The FDA requires pre-market‌ approval for many medical devices and drug-device combination products.

A subsequent ⁤investigation⁤ by ​the Securities ⁤and Exchange Commission‌ (SEC) determined that Nutriband’s transdermal patches constituted a combination of a drug and a delivery device. According to the SEC, such⁢ drug-device combination products require FDA ⁤approval before being marketed. This finding highlighted a critical regulatory‍ oversight by Nutriband.

Timeline of ​Key ⁤Events